TNF Pharmaceuticals Inc (Nasdaq: TNFA), a clinical stage biopharmaceutical company developing novel oral therapies for autoimmune and inflammatory conditions, on Wednesday announced positive clinical data supporting the expansion of its Phase 2b study for isomyosamine, its novel TNF-alpha (TNF-α) inhibitor drug, into multiple indications.
The company has successfully completed an FDA-recommended safety study, which showed favorable results over 13 weeks at all dose levels.
TNFA plans to initiate a Phase 2b clinical trial in early 2025 to assess the efficacy of isomyosamine in treating sarcopenia, a market expected to reach USD4.02bn by 2029. Additionally, the company will launch a study to evaluate isomyosamine as a treatment for GLP-1-induced sarcopenia and frailty in patients using GLP-1 agonists like Wegovy or Ozempic, targeting a rapidly growing USD105bn market by 2029.
Isomyosamine, a novel small molecule, modulates inflammatory cytokines including TNF-α, which plays a key role in aging and various age-related diseases. The TNF inhibitor market alone is projected to reach USD47.3bn by 2029.
NeuroTherapia's Phase 2 Alzheimer's disease trial receives European regulatory approval
Syndax Pharmaceuticals grants share purchase inducement awards to six new employees
Hippo Pharmacy launches fast, free delivery on orders over USD150
Polarean Imaging expands reach with Taiwanese distribution deal
AstraZeneca secures EU recommendation for Imfinzi in limited-stage small cell lung cancer
CHMP recommends EU approval of Daiichi Sankyo and AstraZeneca's datopotamab deruxtecan
Renalys Pharma completes patient enrolment for Phase III clinical trial of sparsentan
NICE recommends ALK's ACARIZAX for house dust mite allergic rhinitis treatment in UK's NHS
Roche's blood test measuring Lp(a) in molar units receives US FDA 510(k) approval
Breckenridge Pharmaceutical's Everolimus Tablets for Oral Suspension receive US FDA approval
Amgen's BLINCYTO (blinatumomab) monotherapy approved in Europe
HeartBeam submits FDA 510(k) application for groundbreaking 12-lead ECG synthesis software
FDA grants Vicore Pharma Fast Track Designation for buloxibutid in idiopathic pulmonary fibrosis
FDA accepts Saol Therapeutics' SL1009 New Drug Application for Priority Review